Fair Market Value at pps of 45 cents (up to $1.10 per share): Market cap of a company in this sector (Drugs/Pharmaceutical; http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/psdata.html )easily reaches 4x the P/S ratio (up to 10x*)...so for an estimated 50M revs in 2019 the RXMD fair market value (and ~450M OS), not even taking its constant expansion into account, should be at a pps of 45 cents in a conservative evaluation (up to $1.10* pps).